Compugen (NASDAQ:CGEN) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research report released on Thursday morning.

Separately, Truist Financial lowered their price objective on shares of Compugen from $5.00 to $4.00 and set a buy rating for the company in a research report on Tuesday, May 21st.

Compugen Price Performance

Shares of NASDAQ:CGEN opened at $1.84 on Thursday. The business’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $2.13. Compugen has a fifty-two week low of $0.53 and a fifty-two week high of $3.03. The stock has a market capitalization of $159.40 million, a price-to-earnings ratio of -9.68 and a beta of 2.60.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.06. The firm had revenue of $6.70 million for the quarter, compared to the consensus estimate of $2.68 million. During the same period in the prior year, the business earned ($0.11) earnings per share. Research analysts expect that Compugen will post 0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

Several hedge funds have recently bought and sold shares of CGEN. Heron Bay Capital Management acquired a new stake in shares of Compugen during the first quarter worth about $32,000. Secure Asset Management LLC acquired a new stake in Compugen during the 2nd quarter worth approximately $69,000. Squarepoint Ops LLC lifted its stake in Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 16,253 shares in the last quarter. Rothschild Investment LLC acquired a new position in shares of Compugen in the second quarter valued at approximately $380,000. Finally, ARK Investment Management LLC increased its position in shares of Compugen by 4.7% during the second quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after acquiring an additional 48,979 shares in the last quarter. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.